NCT07707973Not yet recruitingPhase 2
Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
A Single-arm, Phase II Study of Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 2 Jul 2026
- Start date
- 3 Jul 2026
- Primary completion date
- 3 Jan 2028
- Lead sponsor
- Tianjin First Central Hospital
- Diseases
- Glioblastoma
- NCT number
- NCT07707973
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 3 Jul 2026 to the primary completion date, 3 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 3）Presence of severe comorbidities or active infections, or persistent vomiting that may interfere with the oral administration of temozolomide (TMZ).
Lab values
- 1）EGFR-negative status.
- 2）Prior treatment with chemotherapy, anti-EGFR therapy, or radiotherapy; or a history of other malignancies within the past 5 years.
Who the study is looking for
- 1）Aged 18 to 75 years.
- 2）Newly diagnosed glioblastoma consistent with the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, 5th edition.
- 3）Epidermal growth factor receptor (EGFR)-positive status confirmed by immunohistochemistry (defined as brown-yellow staining in \>10% of tumor cells).
- 4）Partial surgical resection with radiographically measurable residual tumor.
- 5）Karnofsky Performance Status (KPS) score ≥ 50% (with KPS decline attributable to the tumor).
- 6）Adequate renal function, defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance \> 60 mL/min.
- 7）Adequate hepatic function, defined as total bilirubin ≤ 1.5 times the ULN and serum transaminases ≤ 3 times the ULN.
- 8）Adequate hematologic function, defined as a white blood cell count ≥ 3,000/μL or an absolute neutrophil count (ANC) ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 10 g/dL.
- 9）An interval of 2 to 6 weeks between surgical resection and the initiation of radiotherapy (RT).
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.